N-Terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension

[1]  G. Giannakoulas,et al.  Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2007, International Journal of Cardiology.

[2]  S. Iliceto,et al.  Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases , 2006, European journal of clinical investigation.

[3]  W. Gross,et al.  Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease , 2006, European journal of clinical investigation.

[4]  R. Souza,et al.  Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension , 2005, Current medical research and opinion.

[5]  Horst Olschewski,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.

[6]  A. Torbicki,et al.  End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. , 2004, Journal of the American College of Cardiology.

[7]  D. Borderie,et al.  N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. , 2003, Arthritis and rheumatism.

[8]  A. Holmes,et al.  Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2003, Respiratory medicine.

[9]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[10]  C. Ferri,et al.  Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1996, The Journal of rheumatology.

[11]  T. Medsger,et al.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.

[12]  Y. Hasin,et al.  Cardiovascular Effects of Natriuretic Peptides and Their Interrelation with Endothelin-1 , 2004, Cardiovascular Drugs and Therapy.

[13]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[14]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[15]  G. Simonneau,et al.  EFFECTS OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULM HT: A RANDOMIZED PLACEBO CONTROLLED STUDY , 2001 .

[16]  S. Kuribayashi,et al.  Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. , 1998, Journal of the American College of Cardiology.